167 related articles for article (PubMed ID: 36338740)
21. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China.
Wang S; Pei L; Hu T; Jia M; Wang S
Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897
[TBL] [Abstract][Full Text] [Related]
22. Is Menstruation or the Serum Hormone Level a Useful Predictor for Live Birth after Gonadotropin-Releasing Hormone Agonist during Chemotherapy in Young Breast Cancer Patients.
Lee DY; Choi D
Gynecol Obstet Invest; 2017; 82(6):601-606. PubMed ID: 28006769
[TBL] [Abstract][Full Text] [Related]
23. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety investigation of Kuntai capsule for the add-back therapy of gonadotropin releasing hormone agonist administration to endometriosis patients: a randomized, double-blind, blank- and tibolone-controlled study.
Chen JM; Gao HY; Ding Y; Yuan X; Wang Q; Li Q; Jiang GH
Chin Med J (Engl); 2015 Feb; 128(4):427-32. PubMed ID: 25673440
[TBL] [Abstract][Full Text] [Related]
25. Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.
Zhang Y; Xiao Z; Wang Y; Luo S; Li X; Li S
PLoS One; 2013; 8(11):e80444. PubMed ID: 24312222
[TBL] [Abstract][Full Text] [Related]
26. Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice.
Lin QY; Wang YF; Weng HN; Sheng XJ; Jiang QP; Yang ZY
J Zhejiang Univ Sci B; 2012 Nov; 13(11):894-903. PubMed ID: 23125082
[TBL] [Abstract][Full Text] [Related]
27. ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled study.
Rodriguez-Wallberg KA; Nilsson HP; Bergh J; Malmros J; Ljungman P; Foukakis T; Stragliotto CL; Friman EI; Linderholm B; Valachis A; Andersson A; Harrysson S; Vennström L; Frisk P; Mörse H; Eloranta S
BMJ Open; 2023 Dec; 13(12):e078023. PubMed ID: 38070906
[TBL] [Abstract][Full Text] [Related]
28. GnRH agonist therapy to protect ovarian function in young Korean breast cancer patients.
Park HJ; Koo YA; Im YH; Yoon BK; Choi D
J Korean Med Sci; 2010 Jan; 25(1):110-6. PubMed ID: 20054409
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory actions of a gonadotropin-releasing hormone agonist on ovarian follicle-stimulating hormone receptors and adenylate cyclase in vivo.
Ranta T; Baukal A; Knecht M; Korhonen M; Catt KJ
Endocrinology; 1983 Mar; 112(3):956-64. PubMed ID: 6295748
[TBL] [Abstract][Full Text] [Related]
30. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.
Reddy J; Turan V; Bedoschi G; Moy F; Oktay K
J Assist Reprod Genet; 2014 Jul; 31(7):927-32. PubMed ID: 24854484
[TBL] [Abstract][Full Text] [Related]
31. Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles.
Zhou C; Yang X; Wang Y; Xi J; Pan H; Wang M; Zhou Y; Xiao Y
Hum Reprod; 2022 Jul; 37(8):1795-1805. PubMed ID: 35595223
[TBL] [Abstract][Full Text] [Related]
32. Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger?
Lalami I; Labrosse J; Cedrin-Durnerin I; Comtet M; Vinolas C; Krief F; Sifer C; Peigne M; Grynberg M
Reprod Biol Endocrinol; 2022 Jun; 20(1):87. PubMed ID: 35690817
[TBL] [Abstract][Full Text] [Related]
33. GnRH analog administration in patients with polycystic ovarian disease.
Meden-Vrtovec H
Int J Gynaecol Obstet; 1995 Aug; 50(2):179-83. PubMed ID: 7589755
[TBL] [Abstract][Full Text] [Related]
34. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.
Kummer NE; Feinn RS; Griffin DW; Nulsen JC; Benadiva CA; Engmann LL
Hum Reprod; 2013 Jan; 28(1):152-9. PubMed ID: 23077235
[TBL] [Abstract][Full Text] [Related]
35. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy.
Blumenfeld Z; Avivi I; Linn S; Epelbaum R; Ben-Shahar M; Haim N
Hum Reprod; 1996 Aug; 11(8):1620-6. PubMed ID: 8921104
[TBL] [Abstract][Full Text] [Related]
36. The effect of a GnRH agonist on follicular dynamics and response to FSH stimulation in prepubertal calves.
Dufour JJ; Mermillod P; Mariana JC; Romain RF
Reprod Nutr Dev; 1999; 39(1):133-44. PubMed ID: 10222504
[TBL] [Abstract][Full Text] [Related]
37. Gonadotropin-releasing hormone agonist for the preservation of ovarian function in survivors of haematopoietic stem cell transplantation for haematological diseases.
Wang Z; An J; Wang C
BMC Womens Health; 2022 Nov; 22(1):436. PubMed ID: 36345026
[TBL] [Abstract][Full Text] [Related]
38. [Protective effect of GnRH analogues on the reproductive capacity of women with neoplasia or autoimmune disease who require chemotherapy. Final results of a phase ii clinical trial].
Gris-Martínez JM; Trillo-Urrutia L; Gómez-Cabeza JJ; Encabo-Duró G
Med Clin (Barc); 2016 Feb; 146(3):97-103. PubMed ID: 26194532
[TBL] [Abstract][Full Text] [Related]
39. Repeat Dose of Gonadotropin-releasing Hormone Agonist Trigger in Polycystic Ovarian Syndrome Undergoing
Deepika K; Baiju P; Gautham P; Suvarna R; Arveen V; Kamini R
J Hum Reprod Sci; 2017; 10(4):271-280. PubMed ID: 29430154
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Successful Ovarian Protection Using Gonadotropin-Releasing Hormone Agonists During Chemotherapy in Young Estrogen Receptor-Negative Breast Cancer Patients.
Lee DY; Kim JY; Yu J; Kim SW
Front Oncol; 2020; 10():863. PubMed ID: 32656076
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
